The expression and clinical significance of FGF12-AS2 and miR-188-3p in non-small cell lung cancer
Zhou Lili
Cai Maohuai
Liu Qingjing
Abstract：Objective To investigate the expression and clinical significance of long stranded coding RNA(lncRNA)FGF12-AS2 and microRNA-188-3p in non-small cell lung cancer(NSCLC).Method 97 cases of NSCLC patients'cancer tissue and adjacent normal tissue from June 2019 to June 2022 in our hospital were selected as the research subjects.Real-time fluorescence quantitative PCR was used to determine the expression of lncRNA FGF12-AS2 and miR-188-3p.Follow up until June 30,2023,by reviewing hospital medical records,phone calls,WeChat,and outpatient services,the total survival time(OS)of the patient was recorded.Compare the expression of lncRNA FGF12-AS2 and miR-188-3p in cancer tissue and normal tissues adjacent to cancer;compare the expression of lncRNA FGF12-AS2 and miR-188-3p in different pathological features;analyze the relationship between lncRNA FGF12-AS2 and miR-188-3p expression and prognosis in NSCLC patients;Perform multivariate logistic regression analysis on independent risk factors that affect prognosis.Results The expression level of lncRNA FGF12-AS2 in cancer tissues was 2.25±0.67,which was higher than that in adjacent normal tissues(1.00±0.02)(t=18.367,P=0.000).Meanwhile,the expression level of miR-188-3p in cancer tissues(0.43±0.14)was lower than that in normal tissues(1.00±0.01),and the difference was statistically significant(t=39.997,P=0.000).The miR-188-3p expression among cancer tissues of different genders,ages,body mass index,smoking history,tumor diameter,and tissue differentiation degree no statistically significant difference(P>0.05);the cancer group miR-188-3p in stage Ⅲ～Ⅳ lower stage Ⅰ～Ⅱ,and lymph node metastasis lower without lymph node metastasis(P<0.05).The lncRNA FGF12-AS2 expression among different genders,ages,body mass index,smoking history,tumor diameter,and tissue differentiation levels in cancer tissues showed no statistically significant difference(P>0.05);the cancer group expression of FGF12-AS2 in stage Ⅲ～Ⅳ lncRNA higher stage Ⅰ～Ⅱ,and lymph node metastasis higher without lymph node metastasis(P<0.05).The overall survival(OS)time for low expression of miR-188-3p was 22 months,which was significantly shorter than that for high expression of miR-188-3p(32 months)(P<0.05).The OS time for high expression of lncRNA FGF12-AS2 was 23 months,which was significantly shorter than the 31 months for low expression of lncRNA FGF12-AS2(P<0.05).The results of multivariate logistic regression analysis showed that lymph node metastasis,stages Ⅲ～Ⅳ,low expression of miR-188-3p,and high expression of lncRNA FGF12-AS2 were independent risk factors affecting prognosis.Conclusion NSCLC patients have high expression of lncRNA FGF12-AS2 and low expression of miR-188-3p,which is closely related to clinical staging and lymph node metastasis,and is closely related to prognosis.
Keywords：LncRNA FGF12-AS2MiR-188-3pNon small cell lung cancer
Publication Date：2024-12-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 756-760 )